糖尿病混合型高脂血症临床治疗分析

Observation on the effect of Xuezhikang and Rosiglitazone on diabetes patients complicated with hyperlipidemia.

目的观察血脂康与罗格列酮联合用药对2型糖尿病合并混合型高脂血症的影响。方法56例门诊及住院的2型糖尿病合并混合型高脂血症的病人随机分成治疗组28例,应用血脂康胶囊0.6g/2次/d,罗格列酮片4mg/1次/d;对照组28例,单独使用血脂康胶囊0.6g/2次/d。治疗16周,抽血查治疗前与治疗后血清胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、甘油三脂(TG)及前脂蛋白-a(LP-a)水平。结果两组治疗后TC、HDL-C、LDL-C、LP-a水平较治疗前均有显著下降(P<0.01),两组间TG下降幅度差异有显著性(P<0.05),治疗组较对照组TG下降幅度明显增大。结论血脂康与罗格列酮联合治疗2型糖尿病合并混合型高脂血症效果较好,尤其是合并有高甘油三脂血症者。

Objective To evaluate the effect of Xuezhika in combination with rosiglitazone on type 2 diabetic patients with mixed hyperlipidemia. Methods Fifty - six diabetic patients with mixed hyperlipidemia were randomly divided into two groups, each with 28 patients. Patients in Group I were given capsules Xuezhika 0. 6g twice daffy and tablets rosiglitazone 4mg once daily; patients in Group Ⅱ received capsules Xuezhika 0.6g twice daily for a course of 16 weeks. Fasting lipid profile was analyzed at week 0 and week 16. Results The levels of serum total cholesterol（TC）, LDL cholesterol（LDL- C）, and lipoprotein（a） [Lp（a） ] decreased remarkably in the two groups 16 weeks after treatment （P 〈 0.01 ）. The level of triglyceride（TG） decreased slightly in group Ⅱ, but decreased significantly in group Ⅰ, there was significant difference between the two groups （ P 〈 0.05）. Conclusion Xuezhika in combination with resiglitazone is effect on type 2 diabetic patients with mixed hyperlipidemia, especially on those with hypertrlglyceridemia.